Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IFN-γ

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    87 result(s) found for: IFN-γ. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2020-000620-18 Sponsor Protocol Number: RC20_0082 Start Date*: 2021-02-19
    Sponsor Name:Nantes University Hospital
    Full Title: Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the...
    Medical condition: Patients hospitalized in intensive care units, under mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    20.0 100000004862 10076918 Hospital acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001030-29 Sponsor Protocol Number: V212-014 Start Date*: 2014-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults
    Medical condition: Prevention of herpes zoster in adults with autoimmune disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003456-13 Sponsor Protocol Number: DEN-313 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004938-42 Sponsor Protocol Number: EHRVI Start Date*: 2013-03-01
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Experimental Human Rhinovirus Infection, a randomized placebo-controlled pilot study
    Medical condition: Viral infections in general, and the "common cold" induced by HRV-16 in particular.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061494 Rhinovirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003601-10 Sponsor Protocol Number: NL69300 Start Date*: 2020-09-18
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: Treatment of Skin Severity in Ichthyosis with Hyperbaric Oxygen Therapy
    Medical condition: ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10021198 Ichthyosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000896-17 Sponsor Protocol Number: SBP-9200-HBV-206 Start Date*: 2019-05-20
    Sponsor Name:Spring Bank Pharmaceuticals, Inc.
    Full Title: A PHASE 2, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC, HEPATITIS B e ANTIGEN NEGATIVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS AN...
    Medical condition: Chronic HBV-infected, HBeAg-negative subjects, who are non-cirrhotic and meet the cohort-specific criteria. Criteria for the planned cohorts are as follows: Cohort 1 Subjects who have been on NUC t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004311-12 Sponsor Protocol Number: RUTIVAC-1 Start Date*: 2017-02-14
    Sponsor Name:ARCHIVEL FARMA, S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL TO EVALUATE THE IMMUNOMODULATORY EFFECT OF RUTI® IN INDIVIDUALS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) TREATED WITH ...
    Medical condition: High-Risk Non-Muscle-Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000849-50 Sponsor Protocol Number: MI-CP114 Start Date*: 2017-12-12
    Sponsor Name:MedImmune
    Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of...
    Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002233-11 Sponsor Protocol Number: ELISPOT-TC Start Date*: 2020-01-16
    Sponsor Name:Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge
    Full Title: The proposed study is a phase IV, randomized, controlled, multicenter and open clinical trial, with two parallel groups, to evaluate the effectiveness of a preventive strategy against CMV infection...
    Medical condition: We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058666 Cytomegalovirus infection reactivation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001514-34 Sponsor Protocol Number: ILNK15-01 Start Date*: 2012-04-03
    Sponsor Name:Leiden University Medical Center
    Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study
    Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10023685 LAK cell therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001396-33 Sponsor Protocol Number: EPA-COV-001 Start Date*: 2020-11-13
    Sponsor Name:SLA Pharma (UK) Ltd [...]
    1. SLA Pharma (UK) Ltd
    2. KD Swiss GmbH
    Full Title: A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000399-12 Sponsor Protocol Number: GPHIP_0202 Start Date*: 2021-04-16
    Sponsor Name:Grand Medical Pty Ltd
    Full Title: A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe COVID-19 Pneumonia
    Medical condition: severe pneumonia due to COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001070-38 Sponsor Protocol Number: B-pVAC-SARS-CoV-2 Start Date*: 2021-06-21
    Sponsor Name:University Hospital Tuebingen
    Full Title: B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency
    Medical condition: Adults with congenital or acquired B cell/antibody deficiency
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001929-40 Sponsor Protocol Number: AZT_DSTB_BB Start Date*: 2017-11-21
    Sponsor Name:University Medical Center Groningen
    Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis
    Medical condition: Pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037440 Pulmonary tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020150-34 Sponsor Protocol Number: V212-001-01 Start Date*: 2010-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet...
    Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005047-32 Sponsor Protocol Number: H-100-002 Start Date*: 2018-09-27
    Sponsor Name:Hookipa Biotech GmbH
    Full Title: A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero...
    Medical condition: Prevention of clinically significant cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10072247 Cytomegalovirus immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) AT (Completed) NO (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002880-29 Sponsor Protocol Number: 110263 Start Date*: 2007-09-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥66 years) pre...
    Medical condition: Immunization against influenza in male and female subjects aged 66 years and older.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002881-36 Sponsor Protocol Number: 110223 Start Date*: 2007-09-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥67 years) pre...
    Medical condition: Immunization against influenza in male and female subjects aged 67 years and older.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000331-41 Sponsor Protocol Number: CHDR1430 Start Date*: 2016-03-22
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, open-label, vehicle-controlled, parallel, dose-ranging study to assess the pharmacodynamics of topically applied Imiquimod in healthy volunteers
    Medical condition: none, this is a study on healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10062249 Skin inflammation LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000859-27 Sponsor Protocol Number: HS_Apremilast Start Date*: 2017-01-23
    Sponsor Name:Erasmus University Medical Center
    Full Title: Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study.
    Medical condition: Hidradenitis suppurativa, acne inversa, ectopic acne
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:46:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA